Pre-market earnings ahead: TMS Co., Ltd. (4891.T) JPX at JPY 146.00: what to watch for Jan 20
The market is watching 4891.T stock ahead of TMS Co., Ltd.’s earnings announcement on 20 January 2026. In pre-market trading on the JPX the share sits at JPY 146.00, up JPY 1.00 (0.69%) from the prior close. Investors will focus on clinical progress for TMS-007, cash reserves per share of JPY 67.81, and guidance that could move this biotech stock before the open.
4891.T stock: Pre-market snapshot and key price metrics
TMS Co., Ltd. (4891.T) trades on the JPX and opened pre-market at JPY 145.00, with the current price at JPY 146.00 and intraday range JPY 143.00–146.00. Daily volume stands at 273,600 versus an average volume of 288,615, signalling near-normal liquidity. The 52-week range is JPY 120.00–314.00, showing past volatility and a high-water mark the market may re-test if positive clinical news arrives.
4891.T earnings: What to watch in the Jan 20 report
Earnings day on 20 January 2026 will centre on R&D milestones and cash runway rather than conventional sales growth. TMS reported EPS of -15.64 and a negative PE of -9.34 last reported. Investors should watch commentary on TMS-007 Phase 2a follow-ups, any updated timelines for TMS-008, and expense guidance that affects net loss and diluted shares.
4891.T analysis: Financials, balance sheet and valuation
TMS has a market cap of JPY 6,640,920,522.00, book value per share JPY 65.78, and cash per share JPY 67.81, giving a strong liquidity buffer. The company shows current ratio 23.99, reflecting cash-heavy balance sheet and minimal liabilities. Price-to-book sits at 2.22, while operating metrics show negative ROE -22.94% and ROA -21.47%, common for clinical-stage biotech firms.
Technicals and market context for 4891.T stock
Momentum indicators show buying pressure: RSI 62.77, MACD histogram 2.03, and CCI 150.80. Short-term moving averages support the price at 50-day avg JPY 136.60 and place the 200-day average at JPY 150.61. In Japan’s Healthcare sector, peers trade at an average PB near 2.28, placing TMS close to sector valuation on a PB basis.
Meyka AI grade and forecast for 4891.T stock
Meyka AI rates 4891.T with a score out of 100: 62.25 / Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The internal model highlights strong cash per share but flags negative earnings and early-stage clinical risk.
Meyka AI’s forecast model projects a monthly target of JPY 154.64 (implied +5.92% vs JPY 146.00) and a quarterly target of JPY 140.32 (implied -3.90%). Forecasts are model-based projections and not guarantees. Short-term price targets: JPY 155.00 (base), JPY 220.00 (bull), JPY 120.00 (bear).
Risks, catalysts and trading strategy for 4891.T stock
Primary catalysts are clinical updates for TMS-007 and trial pathway news with partner universities. Key risks include continued negative EPS, small float, and clinical setbacks that could trigger sharp moves. Active traders may use the pre-earnings window for event-driven setups, while longer-term investors should weigh cash runway and binary clinical outcomes before adding exposure.
Final Thoughts
4891.T stock trades at JPY 146.00 in pre-market on JPX with earnings due 20 January 2026. The core thesis balances strong cash per share (JPY 67.81) and tangible book value against negative EPS (-15.64) and clinical-stage risk. Meyka AI’s model gives a near-term monthly projection of JPY 154.64, implying +5.92% upside, and a quarterly projection of JPY 140.32, implying -3.90% downside. Our view: expect volatility on the print and focus on management comments about clinical timelines and cash use. Use tight risk controls around earnings, and consider position sizing that reflects the binary trial risk. Meyka AI provides this as an AI-powered market analysis platform; forecasts are model projections, not guarantees, and this is not financial advice.
FAQs
When does TMS (4891.T) report earnings?
TMS Co., Ltd. (4891.T) is scheduled to announce earnings on 20 January 2026. Expect updates on clinical programs, cash runway, and loss guidance that could move the stock in pre-market and intraday trading.
What are the main financial risks for 4891.T stock?
Key risks include ongoing negative EPS (-15.64), limited revenue, and binary clinical outcomes. Despite strong cash per share (JPY 67.81), further trial costs could dilute value if milestones slip.
What price targets does Meyka AI give for 4891.T stock?
Meyka AI projects a monthly target of JPY 154.64 (+5.92% vs JPY 146.00) and a quarterly target of JPY 140.32 (-3.90%). These are model-based projections and not guarantees.
How liquid is trading for 4891.T on the JPX?
Pre-market volume is 273,600 against an average of 288,615, showing near-average liquidity. The share float is modest, so news can cause outsized moves.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
